行情

BIIB

BIIB

生物基因
NASDAQ

实时行情|Nasdaq Last Sale

281.95
+0.81
+0.29%
盘后: 283.99 +2.04 +0.72% 19:40 01/28 EST
开盘
283.96
昨收
281.14
最高
284.29
最低
280.72
成交量
113.66万
成交额
--
52周最高
338.87
52周最低
215.78
市值
520.05亿
市盈率(TTM)
9.98
分时
5日
1月
3月
1年
5年

分析师评级

32位分析师的综合评级

中性

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

BIIB 新闻

  • Top Health Care Stocks for February 2020
  • Investopedia.12小时前
  • Looking Back at 2019
  • GuruFocus.com.1天前
  • Biogen's Alzheimer's Drug Has 'Decent Shot' At FDA Approval, Analyst Says
  • Benzinga.1天前
  • Biogen's Alzheimer's Drug Has 'Decent Shot' At FDA Approval, Analyst Says
  • Benzinga.1天前

更多

所属板块

制药
+0.48%
制药与医学研究
+0.58%

热门股票

名称
价格
涨跌幅

BIIB 简况

Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, and other anti-CD20 therapies. The Company's product candidate includes OCREVUS; Biosimilar adalimumab; Aducanumab; E2609; BIIB074; BAN2401; Opicinumab; CIRARA; BIIB061; BIIB054; BIIB067, and BIIB068.
展开

Webull提供Biogen Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。